Headline: GSK Forecasts Slower Sales Growth in 2026 - GSK (LON:GSK)

[Para 1: The Lead] GSK, under new CEO Luke Miels, forecasts slower sales growth of 3% to 5% in 2026, marking a shift in strategy to expand its pipeline in response to patent expirations for its top-selling HIV drugs. This outlook was presented for the first time since Miels' appointment. [Para 2-3: Supporting details & Context] In 2025, GSK reported a 7% revenue increase at constant currency rates. The company anticipates a more modest growth rate this year, reflecting efforts to diversify its portfolio. GSK's strategy aims to mitigate the impact of patent expirations on its top-line performance. The forecast is based on current market conditions and does not include any unexpected changes in the pharmaceutical industry or global health dynamics.